Effective 19 July 2019, our company email address has been changed from "info@newbinnovation.com" to "info@newbetainnovation.com".
Effective 3 June 2019, our company name has been changed from "New B Innovation Limited" to "New Beta Innovation Limited".
Please note that the company structure, the current contracts and agreements as well as the Chinese company name “新行健醫藥科技有限公司” remain unchanged.
The First-in-Human (FiH) healthy volunteer study to evaluate safety on the use of YQ23 has commenced on 11 Jan 2019. This study is mainly to assess the safety, tolerability and pharmacokinetics (PK - the amount of study drug in the blood) of ascending single dose of YQ23 in healthy male and female subjects. The clinical trial is conducted at a Phase 1 centre in UK and will enroll approximately 40 subjects.
New Beta Innovation receives approval from the Hong Kong Department of Health (DoH) to proceed with a Phase 1 Clinical Trial (First-in-Patient) of YQ23 in patients with advanced tumors.
YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.
New Beta Innovation receives UK Medicines and Healthcare products Regulatory Agency (MHRA) approval to proceed with a Phase 1 Clinical Trial (First-in-Human) of YQ23 in healthy volunteers.
YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.
